Login
Request a demo

Category: Uncategorized

Categories
Uncategorized

Beyond the CE Mark: How can we achieve Medtech Reimbursement in France, Dr. Benoit Salaun?

Dive deep into the heart of French market access with Dr. Stefan Walzer and Dr. Benoit Salaun on this episode of the Map Podcast. As experts in their fields, they dissect the intricacies of the French healthcare system, focusing on medical device reimbursement, and revealing the critical steps to success in this competitive landscape.

This episode is a goldmine for healthcare professionals, medtech innovators, and market access strategists seeking to penetrate the French market effectively. Gain unparalleled insights into securing the optimal position and price for your medical device in France. Embark on your journey to mastering French market access with expert guidance—listen today!

Listen to the podcast: here

Categories
Uncategorized

How can we overcome the complexity of market access for medical devices in Spain, Sergio Gil?

Embark on a captivating journey into the heart of Spain’s healthcare industry with this enthralling episode of the Market Access podcast. Discover the vibrant world of medical devices in Spain and unlock the secrets to navigating this diverse market.

Sergio Gil, a luminary in the medical device realm with over 30 years of experience, takes us through the intricacies of Spain’s healthcare system. Dive deep into the unique challenges and opportunities that define Spain’s market, from its regional healthcare autonomy to the complex puzzle of reimbursement strategies.

This is a must-listen for startups aiming to launch in Spain and established companies seeking to expand their presence. Join us to navigate the complexities of Spain’s healthcare sector and position your company for success in this exciting market!

Listen to the podcast: here

Categories
Uncategorized

The Startup Guide to Navigating Healthcare Reimbursement, Featuring Ron de Graaff

Dive into the heart of healthcare’s financial ecosystem with our electrifying new podcast episode, where Dr. Stefan Walzer, CEO, converses with the legendary Ron de Graaff, a titan in healthcare reimbursement since 1978. Ron’s journey through the evolving healthcare reimbursement landscape reveals not just the history but the future of navigating this complex world.

This episode is a treasure trove for anyone within the healthcare sphere, especially startups aiming to conquer the labyrinth of reimbursement. Embark on a journey to grasp the nuances of reimbursement strategy, the significance of staying abreast with regulations, and the art of market selection for your innovation.

Listen to the podcast: here

Categories
Uncategorized

AMNOG 2.0 – significant changes for the industry since January 2023, correct – Dr. Flume?

Embark on an illuminating expedition into the heart of Germany’s pharmaceutical landscape! Join host Stefan Walzer and esteemed guest Matthias Flume, pharmacist and leader of a regional physicians association, as they delve into the transformative world of the AMNOG (Arzneimittelmarktneuordnungsgesetz) 2.0 reforms, spotlighting the pivotal 2023 updates.

Prepare to be engrossed by a narrative that not only scrutinizes the current state of pharmaceutical regulations but also ventures into speculative territory regarding future shifts. Tune in to gain valuable insights into the evolving dynamics of healthcare in Germany!

Listen to the podcast: here

Categories
Uncategorized

How does the German evaluation committee work, Prof. Jürgen Wasem?

Dive into the complex world of healthcare reimbursement in Germany with this podcast episode, where the market access expert, Dr. Stefan Walzer, unlocks the intricacies of evaluating and integrating new diagnostic methods into the outpatient reimbursement catalogue. Join us as we explore the critical requirements for assessment, the pivotal role of the evaluation committee, a sub-committee of the German Federal Committee (G-BA), and the nuanced process of price setting in this unique healthcare landscape.

In an enlightening conversation with Prof. Jürgen Wasem, the Head of the arbitration board for the evaluation committee, we peel back the layers of this rigorous evaluation process, offering listeners an exclusive look at the inner workings of healthcare reimbursement decisions and the strategic considerations behind them.

Listen to the podcast: here

Categories
Uncategorized

How will the US Inflation Reduction Act change pricing of pharmaceuticals, Anita Burrell?

Brace yourself for a groundbreaking episode on the MAP podcast that delves into the monumental shifts brought about by the Inflation Reduction Act (IRA) in the US pharmaceutical industry. Dr. Stefan Walzer and Anita Burrell MBA, experts in market access, unpack the seismic changes on the horizon as the IRA sets to renegotiate drug prices for Medicare and Medicaid, signaling an unprecedented departure from traditional pricing mechanisms.

This pivotal move by the US government, aimed at funding pharmaceuticals for populations over 65 and vulnerable groups, is poised to reshape the economic landscape, potentially leading to a ripple effect across the private insurance sector and a consequent decline in drug prices. With the prospect of reduced revenues, the discussion also ventures into speculative territory, exploring the implications for the availability of pharmaceuticals both within the US and globally.

Listen to the podcast: here

Categories
Uncategorized

How to be successful in Canadian health care market access & pricing!

Unravel the complexities of Canadian health care reimbursement with a must-listen episode from the MAP podcast. Join Dr. Stefan Walzer, alongside Canadian health care experts Louise Perrault and Nicole Tunstall, as they demystify the process, spotlighting the unique challenges and opportunities within Quebec’s system. Dive deep into the essentials of successful market access strategies, from understanding the key requirements to negotiating and agreeing on prices within Canada’s intricate health care landscape.

This episode is an invaluable resource for anyone looking to navigate the Canadian health care reimbursement maze with confidence. Gain insights into the early steps crucial for planning success and discover the nuances of pricing in a system characterized by diverse institutions and negotiation dynamics. Don’t miss out on this comprehensive guide to conquering Canadian health care reimbursement challenges.

Listen to the podcast: here

Categories
Uncategorized

The AMNOG process – how does it work from a legal perspective, Alexander Meier?

Dive into the heart of Germany’s AMNOG process in this podcast episode, where the intersection of law and market access unfolds. Join Dr. Stefan Walzer, an AMNOG expert, and Alexander Meier, an experienced market access lawyer, as they explore the pivotal role of legal expertise in navigating the complexities of introducing innovative drugs in Germany. This engaging discussion sheds light on the crucial contributions of lawyers, from shaping negotiation strategies to finalizing legal contracts at the conclusion of the AMNOG process.

Discover the synergy between law and market access, and how this collaboration is instrumental in the successful launch of new drugs. Whether you’re a professional in the pharmaceutical industry or just fascinated by the interplay of law and healthcare, this episode offers unique insights into the AMNOG process and the role of legal professionals.

Listen to the podcast: here

Categories
Uncategorized

The UK market access has always been complex, now even more than before, Graham Foxon and Paul Craddy?

Step into the evolving landscape of UK market access post-Brexit with our illuminating podcast episode. Dr. Stefan Walzer brings together market access mavens, Dr. Paul Craddy and Dr. Graham Foxon from Remap Consulting, to unravel the complexities and uncover the new innovation pathways that have emerged in the UK, spanning England, Wales, Ireland, and Scotland. This discussion goes beyond the basics, exploring how to navigate the unique market access avenues for both traditional and digital health products in a post-Brexit era.

Whether you’re seeking the best strategy for introducing your product to the UK market or curious about the latest in digital health pathways, this episode is packed with invaluable insights. Join us as we dive deep into the critical questions shaping market access in the UK today.

Listen to the podcast: here

Categories
Uncategorized

Dutch payers are pragmatic, especially when discussing medical devices, isn’t it, Ron de Graaff?

Unlock the secrets of navigating the Dutch healthcare market with this podcast episode! Dr. Stefan Walzer teams up with Ron de Graaff, a master of market access in the Netherlands, to delve into the unique intricacies and opportunities that define the path for medical devices. Discover the blend of standard and pragmatic approaches of evidence-based medicine assessments and reimbursement processes in the Netherlands. Whether you’re a seasoned professional or new to the healthcare industry, this episode is packed with essential insights and strategies for anyone looking to make a mark in the Dutch healthcare market.

Listen to the podcast: here